These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Buprenorphine Market Analysis and Price Projections
Market Overview
The buprenorphine market is experiencing significant growth driven by several key factors, including the increasing prevalence of opioid addiction, chronic pain disorders, and government investments in healthcare.
Market Size and Growth
The global buprenorphine market was valued at USD 6.22 billion in 2024 and is projected to reach USD 35.75 billion by 2037, growing at a CAGR of 14.4% during the forecast period[1].
Another estimate suggests the market size was USD 6.07 billion in 2024 and is expected to exceed USD 31.27 billion by 2036, also at a CAGR of 14.4%[1].
Growth Drivers
Increasing Opioid Addiction
The rising cases of opioid addiction globally are a major driver. According to the World Health Organization (WHO), opioid use disorders affect over 16 million people worldwide and more than 2.1 million people in the United States annually[4].
Chronic Pain Disorders
The growing prevalence of chronic pain disorders, including cancer, which accounted for about 10 million deaths in 2020, is another significant factor[1].
Government Investments
Escalating government investments in healthcare, particularly in developed nations, are also driving market growth[1].
Effective Treatment Options
Buprenorphine's unique mechanism of action, lower risk of overdose, and clinical efficacy in various formulations have led to its recommendation as a first-line treatment for chronic pain and opioid use disorder by major health agencies[4].
Market Segmentation
Route of Administration
The market is segmented by route of administration into sublingual, transdermal, and buccal. The sublingual segment is anticipated to hold the largest share due to rapid drug absorption, first-pass metabolism, and quick onset of action[1].
The buccal dosage segment is also expected to witness notable growth as more people opt for oral drugs over injection-based treatments[1].
Geographical Analysis
North America is set to account for the largest revenue share by 2036, driven by the strong presence of market players and a high percentage of the population suffering from opioid dependency[1].
Europe and the Asia Pacific region are also expected to contribute significantly to market growth, with the Asia Pacific region projected to be the fastest-growing market[1][4].
Buprenorphine Hydrochloride Market
Market Size and Forecast
The global Buprenorphine Hydrochloride Market was valued at USD 148.5522681 million in 2023 and is projected to reach USD 178.09 million by 2032, growing at a CAGR of 2.3%[2].
Another estimate suggests the market size was USD 135.67 million in 2023 and is projected to reach USD 178.09 million by 2030, growing at a CAGR of 4.62%[3].
Applications and Types
Buprenorphine hydrochloride is used as an analgesic and opioid antagonist. The market is segmented by type into tablets and injections[2].
Buprenorphine and Naloxone Market
Market Size and Growth
The Buprenorphine and Naloxone Market is expected to reach USD 4.73 billion in 2024 and grow at a CAGR of 4.23% to reach USD 5.82 billion by 2029[4].
Key Factors
The market growth is driven by the increasing prevalence of substance use disorders and the advantages of using buprenorphine and naloxone, which offer safer and effective treatment options for opioid addiction and chronic pain[4].
Challenges and Restraints
Stigma and Misconceptions
Stigma and misconceptions regarding the use of buprenorphine and naloxone combination drugs, such as Suboxone, are significant restraints in the market[4].
Regulatory Constraints
Stringent regulatory constraints also pose a challenge to market growth[4].
High Cost of Drugs
The increased and higher cost of these drugs may limit market growth in the near future[2].
Key Players
Prominent players in the buprenorphine market include Indivior PLC, Viatris Inc. (Mylan Inc.), Sandoz AG, Dr. Reddy's Laboratories Ltd., and Hikma Pharmaceuticals PLC for the buprenorphine and naloxone segment[4].
Other key players include Resonance-labs, Unichemlabs, Noramco, Siegfried, Faranshimi, Johnson Matthey, Rusan Pharma, Mallinckrodt, Sanofi, Sun Pharma, Mocind, Sinopharm, and Arevipharma for the buprenorphine hydrochloride segment[2].
Regional Insights
North America
North America is expected to account for the largest revenue share due to the strong presence of market players and a high percentage of the population suffering from opioid dependency[1][4].
Asia Pacific
The Asia Pacific region is projected to be the fastest-growing market, driven by the rising patient pool and growing awareness about the health benefits of buprenorphine[1][4].
Key Takeaways
The buprenorphine market is driven by the increasing prevalence of opioid addiction, chronic pain disorders, and government investments in healthcare.
The sublingual route of administration is expected to dominate the market due to its rapid drug absorption and quick onset of action.
North America and the Asia Pacific region are key geographical segments driving market growth.
Stigma, regulatory constraints, and high drug costs are significant challenges to market expansion.
FAQs
What is the current size and projected growth of the buprenorphine market?
The global buprenorphine market was valued at USD 6.22 billion in 2024 and is projected to reach USD 35.75 billion by 2037, growing at a CAGR of 14.4%[1].
Which region is expected to dominate the buprenorphine market?
North America is set to account for the largest revenue share by 2036, driven by the strong presence of market players and a high percentage of the population suffering from opioid dependency[1].
What are the main applications of buprenorphine hydrochloride?
Buprenorphine hydrochloride is used as an analgesic and opioid antagonist[2].
Who are the key players in the buprenorphine and naloxone market?
Key players include Indivior PLC, Viatris Inc. (Mylan Inc.), Sandoz AG, Dr. Reddy's Laboratories Ltd., and Hikma Pharmaceuticals PLC[4].
What are the major challenges facing the buprenorphine market?
Stigma and misconceptions regarding the use of buprenorphine and naloxone, stringent regulatory constraints, and the high cost of drugs are significant challenges[2][4].
Cited Sources
Research Nester: Buprenorphine Market Size & Share, Growth Trends 2037[1]
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
